Is LENZ Therapeutics' Valuation Justified Amid Rising Global Momentum for VIZZ?

The biopharmaceutical sector has long been a magnet for speculative investing, but few stories in 2025 have captured investor imagination as dramatically as LENZ Therapeutics' launch of VIZZ™, its first FDA-approved treatment for presbyopia. With a global market for presbyopia treatments projected to grow at a 5.5% CAGR through 2033, the question of whether LENZ's valuation is justified hinges on a delicate balance between its product's commercial potential and the company's current financial realities.

VIZZ's Market Position and Early Success

VIZZ, a once-daily preservative-free eye drop, leverages aceclidine to contract the iris sphincter muscle, creating a pinhole effect that extends depth of focus. Its October 2025 launch was met with rapid adoption: by Q4 2025, the product generated $1.6 million in net revenue, with over 20,000 prescriptions filled and 6,500 unique eye care professionals (ECPs) prescribing it. Notably, 55% of these ECPs prescribed VIZZ multiple times during the quarter, signaling strong clinical confidence.

The product's competitive edge lies in its longer duration of action (up to 10 hours) and a lower incidence of side effects compared to rivals like AbbVie's Vuity and Opthea's Ryzumvi. Analysts project VIZZ could achieve peak global sales of $1.1 billion by 2038, a figure that assumes sustained market share gains in a sector dominated by traditional solutions like reading glasses and contact lenses.

Valuation Metrics and Peer Comparison

LENZ's valuation, however, appears disconnected from its current revenue base. As of January 2026, the company trades at a , far exceeding the peer average of 3.9x and the industry average of 4.3x. This premium reflects investor optimism about VIZZ's long-term potential but raises concerns about overvaluation. For context, competitors like AbbVie (ABBV) and Opthea (OCUL) trade at significantly lower P/S ratios, despite having more diversified product portfolios.

The disconnect is further highlighted by LENZ's financials. While the company has no debt and a robust current ratio of 12.69, it reported a net loss of $58.883 million in Q4 2025. Analysts project breakeven by 2027 and profitability by 2028, but these timelines hinge on VIZZ's ability to scale rapidly. Revenue is forecasted to grow at 45.2% annually, yet the company's 2025 Q4 revenue of $1.6 million implies a long path to meaningful scale.

Growth Potential vs. Valuation

The presbyopia market's size-$10.73 billion in 2025 and projected to reach $16.47 billion by 2033-provides a compelling backdrop for VIZZ's growth. However, the product's success is not guaranteed. While VIZZ's mechanism of action is novel, it faces competition from established players and must overcome patient and physician inertia. For instance, AbbVie's Vuity, launched in 2023, has already secured a first-mover advantage, and Opthea's Ryzumvi, approved in 2024, offers a similar pharmacological approach.

LENZ's expansion into international markets, including a partnership with Lunatus in the Middle East, and its planned direct-to-consumer (DTC) campaign with Sarah Jessica Parker, could accelerate adoption. Yet, these initiatives come with high costs. The company's SG&A expenses, driven by commercialization efforts, have already strained its profitability.

Risks and Considerations

The most pressing risk is the mismatch between the current valuation and near-term financial performance. LENZ's P/S ratio has declined by 90% since October 2025, reflecting a correction in investor sentiment as the company's revenue growth lags expectations. While the product's early adoption is encouraging, scaling to $1.1 billion in sales by 2038 would require overcoming significant hurdles, including pricing pressures, reimbursement challenges, and the entry of generic alternatives.

Additionally, the company's reliance on a single product exposes it to clinical and commercial risks. A setback in VIZZ's lifecycle-such as adverse safety signals or slower-than-expected adoption-could disproportionately impact its valuation.

Conclusion

LENZ Therapeutics' valuation appears to be a bet on the long-term potential of VIZZ rather than its current financial performance. While the presbyopia market's growth trajectory and VIZZ's differentiated profile justify optimism, the 26.6x P/S ratio implies a high degree of confidence in a product that has yet to prove its scalability. For investors, the key question is whether the company can execute on its commercial strategy and capture a meaningful share of the $1.1 billion peak sales projection. Until then, the valuation remains a speculative play, with upside potential contingent on VIZZ's ability to outperform expectations in a competitive landscape.